| RTOG Tissue Array Index |
| 23-Jan-2009 (Click on the study number for summary details of the protocol.) |
| Array No. |
Disease Site |
Total Cores |
Total Cases |
RTOG Study # |
RTOG StudyName |
| 01 |
Prostate |
50 |
50 |
8531 |
ZOLADEX + RT IN UNFAVORABLE PROGNOSIS PROSTATE CARCINOMA |
| 8610 |
ZOLADEX & FLUTAMIDE USED AS CYTOREDUCTIVE AGENTS - PROSTATE
|
| Brain |
50 |
50 |
7401 |
MALIGNANT GLIOMAS |
| 7611 |
NEUTRON GLIOMA |
| 7918 |
MISONIDAZOLE GLIOMA |
| 8007 |
NEUTRON ASTROCYTOMA + GLIOBLASTOMA |
| 8201 |
TREATMENT OF
GLIOBLASTOMA HYPERFRACTIONATION |
| 8302 |
RANDOMIZED PHASE II
HYPERFRACTIONATION - GLIOMA |
| Head & Neck
|
50 |
50 |
9501 |
HEAD & NECK: RT VS. RT PLUS CHEMO |
| |
| 02 |
Prostate |
30 |
14 |
8610 |
ZOLADEX & FLUTAMIDE USED AS CYTOREDUCTIVE AGENTS - PROSTATE
|
| |
| 04 |
Bladder |
74 |
50 |
8802 |
NEOADJUVANT + MODALITY PROGRAM WITH ORGAN PRESERVATION FOR BLADDER |
| 8903 |
MCV CHEMO AND RT FOR
BLADDER PRESERVATION |
| 9506 |
BLADDER:PRESERVATION/CYSTECTOMY |
| 9706 |
INVADING BLADDER CANCER OF TRANSURETHRAL SURGERY + CISPLATINUM |
| |
| 05 |
Head & Neck |
259 |
259 |
9003 |
HEAD & NECK: 4 ARM COMPARISON OF FX SCHEDULES |
| |
| 06 |
Head & Neck |
179 |
179 |
9003 |
HEAD & NECK: 4 ARM COMPARISON OF FX SCHEDULES |
| |
| 07 |
Brain |
20 |
20 |
7401 |
MALIGNANT GLIOMAS |
| |
| 08 |
Brain |
156 |
156 |
7401 |
MALIGNANT GLIOMAS |
| 8302 |
RANDOMIZED PHASE II HYPERFRACTIONATION - GLIOMA |
| 9006 |
GLIOMA:PHASE III HFX RT & BCNU VS CONVENTIONAL RT & BCNU |
| 9602 |
GLIOMA: PACLITAXEL AND STANDARD RT |
| 9806 |
BRAIN RT + THALIDOMIDE
|
| |
| 09 |
Head & Neck |
160 |
160 |
9501 |
HEAD & NECK: RT VS. RT
PLUS CHEMO |
| |
| 10 |
Brain |
112 |
106 |
7401 |
MALIGNANT GLIOMAS |
| 7903 | MISONIDAZOLE AND NEUTRONS - MALIGNANT GLIOMA |
| 7918 |
MISONIDAZOLE GLIOMA
|
| 8302 |
RANDOMIZED PHASE II HYPERFRACTIONATION - GLIOMA |
| 9006 |
GLIOMA: PACLITAXEL AND STANDARD
RT |
| 9305 |
BRAIN: BCNU & RT +/- RADIOSURGERY |
| 9404 |
BRAIN: ASTROCYTOMA/RT AND BUdR |
| 9602 |
GLIOMA: PACLITAXEL AND STANDARD RT |
| 9806 |
BRAIN RT + THALIDOMIDE
|
| |
| 11 |
Pancreas
|
229 |
229 |
9704 |
PANCREAS: CHEMORADIATION
+/- GEMCITABINE |
| |
| 12 |
Rectum
|
38 |
38 |
0012 |
RECTUM:
PREOPERATIVE COMBINED MODALITY CHEMORADIATION
|
| |
| 13 |
Esophagus |
191 |
59 |
9405 |
ESOPHAGUS: CHEMO PLUS RT/LOW DOSE VS. HIGH DOSE |
| |
| 14 |
Cervix |
62 |
62 |
0128 |
CERVIX: RT AND CELEBREX/CISPLATIN |
| |
| 15 |
Endometrium |
22 |
22 |
9708 |
ENDOMETRIUM: POST OP RT WITH TAXOL/CISPLATIN |
| |
| 16 |
Endometrium |
19 |
19 |
9905 |
ENDOMETRIUM: ADJUVANT RT +/- CHEMO FOLLOWING TAH/BSO |
| |
| 17 |
Larynx |
45 |
45 |
9111 |
LARYNX: 3 ARM STUDY FOR LARYNGEAL PRESERVATION |
| |
| 18 |
Vocal cord |
105 |
105 |
9512 |
T2 VOCAL CORD: ONCE A DAY VS TWICE A DAY RT |
| |
| 19 |
Brain |
87 |
87 |
0211 |
BRAIN: RT AND IRESSA (ZD 1839) |
| |
| 20 |
Anal |
284 |
284 |
9811 |
CARCINOMA OF THE ANAL CANAL |
| |
| 21 |
Prostate
|
30 |
14 |
8610 |
ZOLADEX & FLUTAMIDE USED AS CYTOREDUCTIVE AGENTS - PROSTATE
|
| |
| 22 |
Pancreas |
225 |
225 |
9704 |
PANCREAS: CHEMORADIATION
+/- GEMCITABINE |
| |
| 23 |
Sarcoma |
51 |
37 |
9514 |
HIGH-RISK,HIGH-GRADE, SOFT TISSUE SARCOMAS |
| |
| 24* |
Head & Neck |
|
259 |
9003 |
HEAD & NECK: 4 ARM COMPARISON OF FX SCHEDULES |
| |
| 25* |
Head & Neck |
|
179 |
9003 |
HEAD & NECK: 4 ARM COMPARISON OF FX SCHEDULES |
| |
| 26* |
Head & Neck |
|
122 |
0234 |
ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK RT + C225 |
| |
| 27* |
Prostate
|
|
39 |
8610 |
ZOLADEX & FLUTAMIDE USED AS CYTOREDUCTIVE AGENTS - PROSTATE |
| |
| 28* |
Brain |
|
20 |
7401 |
MALIGNANT GLIOMAS |
| |
| 29* |
Brain |
|
97 |
0211 |
BRAIN: RT AND IRESSA (ZD 1839) |
| |
| 30* |
Brain |
|
156 |
7401 |
MALIGNANT GLIOMAS |
| 8302 |
RANDOMIZED PHASE II
HYPERFRACTIONATION - GLIOMA |
| 9006 |
GLIOMA: PHASE III HFX RT & BCNU VS CONVENTIONAL RT & BCNU
|
| 9602 |
GLIOMA: PACLITAXEL AND STANDARD RT |
| 9806 |
BRAIN RT + THALIDOMIDE |
| |
|
| *Planning phase |
